

# Global Cancer Biological Therapy Market 2016: Industry Research, Review, Growth, Segment and Analysis to 2021

*Europe, Middle East & Africa (EMEA)  
Cancer Biological Therapy Market  
Information, by phase (phase I, phase II,  
phase III), by type, by end users - Forecast  
to 2021*

PUNE, MAHARASHTRA, INDIA, October  
18, 2016 /EINPresswire.com/ --


Intended Audience

- Cancer Biologics product manufacturers
- Oncology Research Centers
- Research and Development (R&D) Companies
- Government Research Laboratories
- Government and Independent Regulatory Authorities



The Major Key Players are mgen Inc (US), Bristol-Myers Squibb Company (US), CELGENE CORPORATION (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (SWITZERLAND), Merck & Co., Inc, Novartis AG"

*Market Research Future*



- Market Research and Consulting Service Providers
- Cancer Research Institutes and Universities

Segments:

EMEA [cancer biological therapy market](#) has been segmented

On the basis of phase which comprises of phase I, phase II, and phase III.

On the basis of type the market is segmented into monoclonal antibodies, interferon, interleukins, cancer growth inhibitors, gene therapy, colony stimulating factors,


targeted therapy, and cancer vaccines.

On the basis of end users the market is segmented into hospitals & clinics, cancer research centers, laboratories.

Europe, Middle East & Africa (EMEA) [cancer biological therapy](#) market will cross the mark of USD 29.0 billion by 2021:

Market Scenario:

[Market research future](#) published a cooked research report on EMEA cancer biological therapy that contains the information from 2013 to 2021. The EMEA cancer biological therapy market is expected to grow with the CAGR of 5.2% from 2016 to 2021, and with this, it is expected to cross \$29 billion by 2021.



Request a Sample Copy @

<https://www.marketresearchfuture.com/sample-request/europe-the-middle-east-and-africa-cancer-biologic-therapy-market-forecast-to-2021>

The Hottest Trend in the Market

Cancer biological therapy is designed and decided on patient's immune system and response while other treatments are based on cell gesturing. Normally it is understood that the immune system can identify and terminate the foreign cells or abnormal cells to prevent the tumor formation. Cancer biological therapy is one of the most advanced technologies and will help cancer patients all around the globe.

Among the cancer biological therapy types, monoclonal antibodies is compositing the larger growth of the market

Currently monoclonal antibodies carrying radioisotopes prove useful in diagnosing certain cancers, such as colorectal, ovarian, and prostate.

It is projected to the largest-share holding segment of the market from the period of 2013 to 2021. Further it also has promising growth rate during the forecast period from 2016 to 2021.

Europe will continue to be the largest market.

Though, Europe's market is expected to be mature, and the industry will find stagnant growth for this market after next few years. However, the continual technology development may still enhance the growth of these markets.

On the other hand, Middle East & Africa region will be with Qatar, UAE, Kuwait, Bahrain, Oman and Saudi Arabia will show lucrative growth and continue with this trend through the forecast period.

Ask for your specific company profile and country level customization on reports.

This report includes a study of strategies, of major market players. It includes the product portfolios, developments of leading major players such as Amgen Inc (US), Bristol-Myers Squibb Company (US), CELGENE CORPORATION (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (SWITZERLAND), Merck & Co., Inc (US), Novartis AG (Switzerland) and others.

Browse full report with in-depth TOC @ <https://www.marketresearchfuture.com/reports/europe-the-middle-east-and-africa-cancer-biologic-therapy-market-forecast-to-2021>

This research report has provides the insights, on various levels of analyses such industry analysis, market share analysis leading market players and their profiles. This report also helps in studying the target segments by providing views on emerging & high-growth segments and market conclusion. Together the market data comprise and discuss with the basic assessments on the competitive scenarios & strategies, of the EMEA cancer biological therapy market, including the high-growth regions, countries and their political, economic and technological environments. Furthermore the project report also provides the views over the historical market values as well as, pricing and cost analysis of the same.

## Table of Content

1. REPORT PROLOGUE
2. INTRODUCTION
  - 2.1 DEFINITION
  - 2.2 SCOPE OF STUDY:
    - 2.2.1 RESEARCH OBJECTIVE
    - 2.2.2 ASSUMPTIONS & LIMITATIONS
      - 2.2.2.1 ASSUMPTIONS
      - 2.2.2.2 LIMITATIONS
    - 2.2.3 MARKET STRUCTURE:
- 3 RESEARCH METHODOLOGY
  - 3.1 RESEARCH PROCESS
  - 3.2 PRIMARY RESEARCH
  - 3.3 SECONDARY RESEARCH:
- 4 MARKET DYNAMICS
  - 4.1 DRIVERS
    - 4.1.1 INCREASING CANCER SURVIVAL RATE
    - 4.1.2 GROWING DEMAND FOR ADVANCED THERAPIES
  - 4.2 RESTRAINTS
    - 4.2.1 HIGH COST OF CANCER BIOLOGICAL THERAPY
  - 4.3 OPPORTUNITIES
    - 4.3.1 UNTAPPED TYPES OF CANCERS
  - 4.4 MACROECONOMIC INDICATORS
- 5 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY PHASE
  - 5.1 INTRODUCTION
  - 5.2 PHASES
- 6 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY TYPE
  - 6.1 KEY FINDINGS
  - 6.2 MONOCLONAL ANTIBODIES
  - 6.3 INTERFERONS
  - 6.4 INTERLEUKINS
  - 6.5 CANCER GROWTH INHIBITORS
  - 6.6 GENE THERAPY

6.7 COLONY-STIMULATING FACTORS

6.8 TARGETED THERAPY

6.9 CANCER VACCINES

Continued....

#### List of Tables

TABLE 1 EMEA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)

TABLE 2 MONOCLONAL ANTIBODIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2013-2021 (USD MILLION)

TABLE 3 INTERFERONS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021

TABLE 4 INTERLEUKINS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021

TABLE 5 CANCER GROWTH INHIBITORS FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)

TABLE 6 GENE THERAPY FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)

TABLE 7 TARGETED DRUG DELIVERY FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)

TABLE 8 CANCER VACCINES FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)

TABLE 9 EMEA CANCER BIOLOGICAL THERAPY MARKET, BY END-USERS 2013-2021 (USD

TABLE 10 EMEA CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021

TABLE 11 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2013-2021

TABLE 12 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2013-2021 (USD MILLION)

continued....

Purchase a License Copy @

[https://www.marketresearchfuture.com/checkout?currency=one\\_user-USD&report\\_id=616](https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=616)

#### List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACH:

FIGURE 3 MARKET DYNAMICS FOR EMEA CANCER BIOLOGICAL THERAPY MARKET

FIGURE 4 ATTRITION RATE OF PHASE III CLINICAL TRIALS IN EUROPE, 2012 (%)

FIGURE 5 CANCER BIOLOGICAL THERAPY SUCCESS RATES IN VARIOUS PHASES OF CLINICAL TRIALS

FIGURE 6 EMEA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE

FIGURE 7 MONOCLONAL ANTIBODIES MARKET, BY TYPE, 2015 (USD MILLION)

Continued.....

#### Related Report

Global Rheumatoid arthritis Market Research Report- Forecast To 2022

#### About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR)

#### Contact:

Ruwin Mendez

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 (339) 368 6938

Email: [sales@marketresearchfuture.com](mailto:sales@marketresearchfuture.com)

Ruwin Mendez

Market Research Future

+1 (339) 368 6938

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/349881139>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.